SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS)

Posted by Francis Steltz on Aug 13th, 2026

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the target of some unusual options trading on Wednesday. Stock traders bought 61,072 put options on the company. This is an increase of approximately 65% compared to the typical volume of 37,101 put options.

Institutional Trading of SELLAS Life Sciences Group

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Larson Financial Group LLC bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter worth approximately $26,000. BNP Paribas Financial Markets raised its holdings in SELLAS Life Sciences Group by 89.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after acquiring an additional 9,299 shares during the last quarter. Concurrent Investment Advisors LLC purchased a new position in SELLAS Life Sciences Group in the 4th quarter worth approximately $38,000. Beacon Pointe Advisors LLC bought a new position in SELLAS Life Sciences Group in the 4th quarter valued at approximately $38,000. Finally, California State Teachers Retirement System boosted its stake in SELLAS Life Sciences Group by 22.4% during the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock valued at $39,000 after purchasing an additional 1,709 shares during the last quarter. 17.38% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on SLS. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, SELLAS Life Sciences Group currently has a consensus rating of “Hold” and a consensus price target of $10.00.

View Our Latest Stock Analysis on SELLAS Life Sciences Group

SELLAS Life Sciences Group Price Performance

NASDAQ:SLS opened at $11.77 on Thursday. The firm has a market capitalization of $2.31 billion, a P/E ratio of -56.04 and a beta of 2.48. SELLAS Life Sciences Group has a one year low of $1.39 and a one year high of $15.88. The company’s 50-day simple moving average is $11.08 and its 200 day simple moving average is $7.29.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

About SELLAS Life Sciences Group

(Get Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.